Chi‐Chung Li

3.0k total citations · 1 hit paper
56 papers, 1.8k citations indexed

About

Chi‐Chung Li is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Chi‐Chung Li has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Immunology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Chi‐Chung Li's work include CAR-T cell therapy research (18 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Migraine and Headache Studies (13 papers). Chi‐Chung Li is often cited by papers focused on CAR-T cell therapy research (18 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Migraine and Headache Studies (13 papers). Chi‐Chung Li collaborates with scholars based in United States, Canada and Switzerland. Chi‐Chung Li's co-authors include Anuj Chauhan, John Urquhart, Sreeneeranj Kasichayanula, Shen Yin, Michael C. Wei, Yash Kapoor, Iraj Hosseini, Lihua E. Budde, Matthew J. Matasar and Nancy L. Bartlett and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chi‐Chung Li

55 papers receiving 1.7k citations

Hit Papers

Safety and efficacy of mosunetuzumab, a bispecific antibo... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
    2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chi‐Chung Li United States 20 620 398 381 358 331 56 1.8k
Takashi Watanabe Japan 26 608 1.0× 79 0.2× 453 1.2× 213 0.6× 75 0.2× 126 1.9k
Jing Qin China 33 875 1.4× 50 0.1× 132 0.3× 114 0.3× 604 1.8× 105 4.2k
Chian‐Shiu Chien Taiwan 25 669 1.1× 102 0.3× 81 0.2× 107 0.3× 62 0.2× 57 2.8k
Gary L. Peck United States 32 757 1.2× 140 0.4× 279 0.7× 88 0.2× 41 0.1× 72 4.3k
Ana Guzmán‐Aránguez Spain 26 85 0.1× 571 1.4× 25 0.1× 403 1.1× 256 0.8× 63 1.7k
Jiayuan Huang China 28 247 0.4× 88 0.2× 71 0.2× 83 0.2× 137 0.4× 78 1.9k
Xin Yu China 30 744 1.2× 62 0.2× 235 0.6× 48 0.1× 21 0.1× 147 3.1k
Michele Reibaldi Italy 35 175 0.3× 353 0.9× 73 0.2× 1.9k 5.4× 35 0.1× 258 4.3k
Sébastien Taurin United States 27 346 0.6× 51 0.1× 90 0.2× 52 0.1× 112 0.3× 78 2.6k
Jiawen Xu China 23 183 0.3× 211 0.5× 61 0.2× 152 0.4× 157 0.5× 66 1.4k

Countries citing papers authored by Chi‐Chung Li

Since Specialization
Citations

This map shows the geographic impact of Chi‐Chung Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi‐Chung Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi‐Chung Li more than expected).

Fields of papers citing papers by Chi‐Chung Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi‐Chung Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi‐Chung Li. The network helps show where Chi‐Chung Li may publish in the future.

Co-authorship network of co-authors of Chi‐Chung Li

This figure shows the co-authorship network connecting the top 25 collaborators of Chi‐Chung Li. A scholar is included among the top collaborators of Chi‐Chung Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi‐Chung Li. Chi‐Chung Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galluppi, Gerald R., Malidi Ahamadi, Nageshwar Budha, et al.. (2024). Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology & Therapeutics. 116(2). 282–288. 6 indexed citations
2.
Bender, Brendan C., et al.. (2024). Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clinical Cancer Research. 31(2). 245–257. 11 indexed citations
3.
Li, Chi‐Chung, Brendan C. Bender, Justin Wilkins, et al.. (2024). A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics. 117(2). 465–474. 3 indexed citations
4.
Bender, Brendan C., et al.. (2024). Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications. Blood. 144(Supplement 1). 5798–5798. 1 indexed citations
5.
Li, Chi‐Chung, Kapil Gadkar, Genevive Hernandez, et al.. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science. 16(7). 1134–1148. 44 indexed citations
6.
Budde, Lihua E., Laurie H. Sehn, Matthew J. Matasar, et al.. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet Oncology. 23(8). 1055–1065. 244 indexed citations breakdown →
7.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations
8.
Moore, Eric L., Mark E. Fraley, Ian M. Bell, et al.. (2020). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor. Journal of Pharmacology and Experimental Therapeutics. 373(1). 160–166. 51 indexed citations
9.
Moore, Eric L., Christopher S. Burgey, Mark E. Fraley, et al.. (2019). Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021). Neurology. 92(15_supplement). 2 indexed citations
10.
11.
12.
Lü, Dan, Tong Lu, Mark Stroh, et al.. (2016). A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemotherapy and Pharmacology. 77(3). 459–476. 41 indexed citations
13.
Fraser, Iain P., Lingling Han, Tae Hyung Han, et al.. (2012). Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study. Headache The Journal of Head and Face Pain. 52(4). 625–635. 12 indexed citations
14.
Wang, Bosen, Chi‐Chung Li, Sen Lin, et al.. (2011). Magnetic properties and room-temperature magnetocaloric effect in the doped antipervoskite compounds Ga1−xAlxCMn3 (0≤x≤0.15). Journal of Magnetism and Magnetic Materials. 323(15). 2017–2022. 15 indexed citations
15.
Friedman, Evan, Iain P. Fraser, Yinghong Wang, et al.. (2011). Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?. The Journal of Clinical Pharmacology. 51(11). 1561–1570. 30 indexed citations
16.
Sinclair, Simon, Stefanie A. Kane, Bart Van der Schueren, et al.. (2009). Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974). British Journal of Clinical Pharmacology. 69(1). 15–22. 70 indexed citations
17.
Hsiang, Chien‐Yun, Szu‐Yuan Wu, Chi‐Chung Li, et al.. (2009). Comprehensive evaluation of a novel nuclear factor‐κB inhibitor, quinoclamine, by transcriptomic analysis. British Journal of Pharmacology. 157(5). 746–756. 11 indexed citations
18.
Li, Chi‐Chung, et al.. (2007). Timolol transport from microemulsions trapped in HEMA gels. Journal of Colloid and Interface Science. 315(1). 297–306. 84 indexed citations
19.
Li, Chi‐Chung, et al.. (2005). Dispersion of DMPC Liposomes in Contact Lenses for Ophthalmic Drug Delivery. Current Eye Research. 30(12). 1071–1080. 133 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takashi Watanabe Breakdown of academic impact, for papers by Jing Qin Breakdown of academic impact, for papers by Chian‐Shiu Chien Breakdown of academic impact, for papers by Gary L. Peck Breakdown of academic impact, for papers by Ana Guzmán‐Aránguez Breakdown of academic impact, for papers by Jiayuan Huang Breakdown of academic impact, for papers by Xin Yu Breakdown of academic impact, for papers by Michele Reibaldi Breakdown of academic impact, for papers by Sébastien Taurin Breakdown of academic impact, for papers by Jiawen Xu
Rankless by CCL
2026